Study on the Efficacy and Safety of QLM1016 in Schizophrenia

StatusActive, Not Recruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Jul 2026 → Oct 23, 2026
See other at-risk trials from Qilu Pharmaceutical Co., Ltd.

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date changed from estimate of May 2025 to Oct 2, 2025
    • Trial status changed: Not Yet Recruiting → Active, Not Recruiting
    • Primary completion pushed from Jul 2026 to Oct 23, 2026
    • Eligibility criteria expanded, about 5 words
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The study will evaluate the antipsychotic efficacy of QLM1016 in a multicenter, randomized, double-blind, parallel controlled study in patients diagnosed with schizophrenia.
Trial Details
NCT Number NCT06799559
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Schizophrenia
Related terms Schizophrenia
Enrollment 402 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov